Introduction:
With the advent of highly active antiretroviral therapy (HAART), the lifespan of HIV-infected persons is approaching that of the general population. 1 As a result, HIV-infected persons increasingly are diagnosed with chronic age-related non-communicable diseases such as cardiovascular disease (CVD). By age 60, the cumulative CVD incidence has been estimated as 21% in men and 14% in women with HIV infection, compared with 13% and 9%, respectively, in the US general population. 2, 3 HIV infection is associated with chronic inflammation, endothelial dysfunction, platelet activation and coagulopathy; as well as a higher prevalence of CVD risk factors such as diabetes, hypertension and dyslipidemia. 2, 4 The use of HAART may in some circumstances further exacerbate dyslipidemia, diabetes and endothelial dysfunction, 4, 5 and increase the risk of CVD events. 6 These findings all highlight the importance of recognizing the increased CVD risk among HIV-infected adults.
High-sensitivity cardiac troponin (hs-cTnI) has been identified as a novel circulating biomarker of subclinical myocardial damage in asymptomatic adults with no prior history of CVD. 7, 8 Greater levels of hs-cTn are strongly and independently associated with future risk for heart failure, CVD death and all-cause mortality in primary prevention cohorts. [9] [10] [11] [12] However, it is unclear whether hs-cTn elevation reflects primarily subclinical ischemia from occult coronary artery disease, structural heart disease (such as left ventricular hypertrophy, LVH), or a combination of both. Given the Page 
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potential future use of hs-cTn as a biomarker of risk in the primary prevention setting 10 and as a surrogate marker for cardiovascular health, 12 it is important to better understand the underlying mechanisms of hs-cTn elevation in adults without known CVD. Improved understanding of such mechanisms may be achieved by evaluating the relationship between hs-cTn and abnormalities detected using cardiac computed tomography angiography (CCTA). However, few if any rigorously conducted prospective cohorts of primary prevention adults without known CVD have high-quality CCTA data available.
In addition, while an association of HIV infection with increased subclinical coronary atherosclerosis as measured using cardiac CT has been previously shown, 13, 14 much less is known about the association between HIV and myocardial damage as measured by hs-cTn. 13 Therefore, using crosssectional data from a cohort of men without known CVD, with or at risk for HIV, from the Multicenter AIDS Cohort Study (MACS), we sought to examine associations of hs-cTnI with left ventricular mass indexed to body surface area (LVMi) or with coronary anatomy (both measured by CCTA). As a secondary analysis, we assessed whether HIV serostatus modifies these associations.
Methods:
MACS is a prospective cohort study that enrolled HIV-infected and uninfected men who had sex with men. analyses, we also excluded participants reporting any history of CVD events (n=3) and those without available stored blood specimens for hs-cTnI testing (n=298). Men remaining for analysis (n=458) had cardiac CT imaging and hs-cTnI blood samples drawn on the same day.
MACS participants were seen every 6 months for standardized interviews, physical examination, and blood and urine collection. Baseline characteristics included in the current analysis were collected at the preceding MACS study visit closest to CT scanning. Body mass index was calculated as weight in kilograms divided by height in meters squared. Current smoking was self- Participants in the MACS-CVD study underwent a non-contrast CT to assess coronary artery calcium (CAC). If patients met eligibility criteria (see Online Supplement) a contrast-enhanced CCTA was performed using a 64-slice multi-detector scanner at three centers and a 320-slice CT scanner at the fourth center (Johns Hopkins Hospital). 16 A heart rate target of between 50-65 bpm was achieved using oral and/or intravenous beta-blockers or calcium channel blockers as required. CT scans were read centrally at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center.
Coronary plaque was assessed and measured in each of the modified 15 coronary segments outlined by the American Heart Association. assessed as calcified, noncalcified, or mixed (less than 50% area of plaque calcified). CAC scores were calculated using the method of Agatston.
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Measurements of the anteroinferior and septal-lateral diameters in the shortaxis planes at the left ventricular mid-papillary level, and four-chamber longaxis left ventricular cavity lengths were obtained. These measurements were used to calculate left ventricular mass as previously described. 19 We defined LVH as an LVMi ≥ 96 g/m 2 (not including papillary muscles), based on previous studies. Baseline characteristics were compared between participants according to quartiles of hs-cTnI using chi-square for categorical and t-testing for continuous variables. Due to a non-normal distribution, we analyzed hs-cTnI levels as a log e -transformed continuous outcome variable and as a categorical outcome variable (≥ 75 th percentile or < 75 th percentile of the overall sample distribution). We then tested the association of LVMi, coronary artery stenosis severity, and type of coronary artery plaque (calcified, non-calcified and mixed) with the outcome of hs-cTnI using multivariable linear and logistic regressions. We tested LVMi as a continuous exposure variable, categorized in quartiles, and dichotomized as LVH vs no LVH. We subsequently evaluated if HIV serostatus and HAART use were associated with hs-cTnI levels. Finally, we determined whether the associations of LVMi, coronary artery stenosis and coronary artery plaque with hs-cTnI levels are modified by HIV serostatus (positive or negative).
We used hierarchical 4 models with progressive adjustment for covariates. 
Results:
Baseline characteristics of the study participants are presented in Table 1 . Men with the uppermost hs-cTnI quartile had higher body mass index, higher systolic BP, and were more likely to be African American or using diabetes medication than men in the lower quartiles. They were also more likely to have LVH and greater coronary artery stenosis severity on CCTA imaging, without significant differences in plaque composition. There were no differences in the crude proportion of men with HIV within each of the hs-cTnI quartiles.
When left ventricular mass was modeled as a categorical exposure by quartile, the outcome of log-transformed hs-cTnI was higher in the fourth We also examined the relationship between exposure categories of coronary stenosis severity and hs-cTnI as an outcome. In multivariable linear regression analyses with log-transformed troponin level as a continuous outcome variable, there was no significant association between hs-cTnI and severity of coronary artery stenoses ( Tables 2 and 3 ). However, with hscTnI modeled as a binary outcome, the odds ratio of having hs-cTnI ≥75 th percentile was 3.08 (95% CI 1.23 to 7.74) among men with coronary artery stenosis ≥70% even after adjustment for baseline left ventricular hypertrophy (Supplemental Table 1 ). Hs-cTnI levels were not associated with prevalence of any coronary plaque or type of plaque ( Table 2 ). There was also no association between troponin levels with coronary plaque when stratified by HIV serostatus (Supplemental Table 2 ).
Finally, we evaluated the relationship of HIV-specific variables, including HIV serostatus and HAART therapy, with hs-cTnI as the outcome.
There were no significant differences in hs-cTnI levels between HIV-infected and uninfected men ( Table 4 and Supplementary Table 3 ). Among HIVinfected participants, there were also no differences in hs-cTnI level between those receiving or not receiving HAART, and between HAART that did or did not include protease inhibitors.
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Discussion:
The current study adds to our understanding of the association between abnormalities in cardiac anatomy, visualized using CCTA imaging, and high-sensitivity troponin levels in a well-characterized primary prevention cohort of HIV-infected and uninfected men. We also extend prior research by further assessing the relationship between HIV clinical parameters and hs-cTn levels. First, we demonstrate that higher LVMi is associated with subclinical myocardial damage, as indicated by hs-cTnI, among men without known CVD even after adjusting for severity of coronary artery disease. We were unable to adequately assess associations between LVH (as defined by a cutoff LVM of ≥ 96 g/m 2 ) and since there were very few cases with LVH in the MACS-CVD cohort. Abnormalities in coronary luminal anatomy appeared to be less convincingly associated with elevated hs-cTnI levels in the primary prevention sample, though we did find an association with hs-cTnI in the small subgroup (~8%) with coronary artery stenoses ≥ 70%, which are typically considered clinically flow limiting. 21 Second, presence of coronary plaque or plaque type among men with coronary atherosclerosis were not associated with hs-cTnI levels in our study, a result that appears to contradict prior findings. However, the mechanisms underlying this association have been unclear. In the Dallas Heart Study, age, male sex, black race, left ventricular mass and wall thickness by MRI were associated with detectable hs-cTnT, but no independent associations between hs-cTnT and prior history of myocardial infarction or angina, coronary artery calcium, or left ventricular ejection fraction were seen. 9 However, to our knowledge, none of the primary prevention cohorts that have previously studied the determinants of hs-cTn abnormalities had CT angiography imaging information on coronary artery disease and stenosis severity. Hence, it remains poorly understood whether the presence of elevated high-sensitivity troponin levels in adults without known CVD is due to underlying coronary artery disease, to structural heart disease (e.g., higher LVMi reflecting severity of ventricular hypertrophy), or a mix of both. Our results demonstrate that higher LVMi appears more Page 14 of 30 consistently associated with elevated hs-cTnI in populations than subclinical coronary artery disease in primary prevention populations. Because individuals with the highest LVMi are particularly at risk of subclinical myocardial damage, persons without known CVD who are found to have an elevation in hs-cTn may benefit from investigation for structural heart disease (noting that obstructive CAD is also rare in this population). It is unclear if these individuals may also benefit from certain interventions such as more intensive BP reduction to reduce long-term risk. 24 In a small subgroup (<10%) of our sample with overtly asymptomatic though potentially flow limiting coronary stenoses ≥70%, we also found elevated hs-cTnI levels and, as such, careful questioning regarding exercise capacity and chest pain status also appears indicated among adults without known CVD with elevated hs-cTn. Elevated hs-cTn levels have previously been associated with subclinical CAD (as determined by coronary artery calcium measured using non-contrast cardiac CT) in individuals without known coronary artery disease. 25 However this finding has been inconsistent and coronary artery calcium imaging does not any provide information regarding stenosis severity or burden of non-calcified atherosclerosis in the coronary bed. 9 To our knowledge, this is the first study to examine the association between coronary artery disease measured using a more sensitive imaging modality, contrast-enhanced CCTA, and hs-cTn levels among adults without known CVD. Prior analyses evaluating associations between CCTA findings Page 15 of 30 and hs-cTn levels have involved mainly small studies of patients with symptomatic coronary artery disease (typically stable chest pain) who were evaluated clinically using CCTA. In symptomatic patients, hs-cTn levels have been associated with coronary artery disease and severity of stenosis, and, using intravascular ultrasound, have also been associated with total noncalcified plaque and the presence of vulnerable plaque features like positive remodeling or thin-cap fibroatheroma. 26, 27 Our study of men without known CVD would suggest that the associations between coronary disease and hscTn levels are weaker in persons without symptoms and that, in primary prevention, the main driver linking hs-cTn level abnormalities to adverse outcomes appears to be structural heart disease. This consideration is critical in our understanding of using hs-cTn level as a marker of myocardial health in primary prevention and as a possible surrogate outcome in clinical studies. 28 In addition to providing a unique opportunity to explore associations of cardiac structure and coronary anatomy with hs-cTnI levels among men without known CVD, our study also allowed for further assessment of the association between HIV clinical factors and hs-cTnI. HIV-infected persons have a greater prevalence of traditional CVD risk factors and an increased risk of CVD events. While ~40% of this sample was not HIVinfected (but were at risk for HIV), our results may not be generalizable to all persons without known CVD in the community. Further, our sample consisted of a heterogenous mix of men with and without HIV. We do not see this as a major limitation; however, as most observational cohorts contain mixes of demographic features (e.g. diabetics and non-diabetics) and we adjusted for HIV status in our models. Indeed, we are not aware of another large cohort of primary prevention adults who have both CCTA and hs-cTn data available and, hence, needed to leverage this particular cohort to probe the potential anatomical mechanisms underlying subclinical hs-cTn elevation in primary prevention adults. Troponin levels are known to be affected by renal function, 30 and we cannot generalize our findings to those with renal disease given participants with an estimated glomerular filtration rate < 60 ml/min/1.73m 2 were excluded. Other limitations include the observational study design, which cannot rule out residual confounding as a factor in any associations reported.
In our cohort of HIV-infected and uninfected men without known CVD, we found that asymptomatic individuals with elevated hs-cTnI levels were more likely to have increased LVMi and that hs-cTnI levels appeared less associated with coronary artery disease or plaque-type, except in the small Page 
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subgroup of approximately 8% of men with luminal stenosis ≥70%. These findings were apparent in both HIV-infected and uninfected men. The presence of HIV infection itself, nor HIV disease clinical control status nor HAART treatment, did not appear to be associated with hs-cTnI levels in our study. These findings corroborate prior knowledge that abnormalities in hscTn levels among adults without known CVD are more strongly tied to structural heart disease than to coronary artery stenosis. 
